Nutex Health Inc. $NUTX Stake Lessened by Smith Group Asset Management LLC

Key Points

• Smith Group Asset Management cut its Nutex Health stake by 60.8% in the third quarter, leaving it with 5,167 shares valued at approximately $1.09 million. Institutional investors collectively own 5.32% of the company.
• Nutex Health reported quarterly EPS of $9.38, surpassing the $4.95 consensus estimate, while revenue reached $210.75 million. Analysts expect full-year EPS of $27.58.
• Analyst sentiment remains positive, with four Buy ratings and one Hold rating; the stock has a “Moderate Buy” consensus and an average price target of $323.67, compared with its reported price of $212.63.

Smith Group Asset Management LLC lowered its position in shares of Nutex Health Inc. (NASDAQ:NUTX - Free Report) by 60.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 5,167 shares of the company's stock after selling 8,001 shares during the quarter. Smith Group Asset Management LLC owned about 0.08% of Nutex Health worth $1,094,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sterling Capital Management LLC grew its stake in Nutex Health by 9.1% during the third quarter. Sterling Capital Management LLC now owns 1,771 shares of the company's stock worth $375,000 after buying an additional 148 shares during the period. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in shares of Nutex Health during the 3rd quarter valued at $2,117,000. State of Alaska Department of Revenue lifted its holdings in shares of Nutex Health by 243.6% during the 3rd quarter. State of Alaska Department of Revenue now owns 1,000 shares of the company's stock valued at $211,000 after acquiring an additional 709 shares in the last quarter. GK Wealth Management LLC purchased a new stake in Nutex Health during the 3rd quarter worth $73,000. Finally, WINTON GROUP Ltd purchased a new stake in Nutex Health during the 2nd quarter worth $237,000. Institutional investors and hedge funds own 5.32% of the company's stock.

Nutex Health Price Performance

Shares of NUTX stock opened at $212.63 on Thursday. The firm has a fifty day simple moving average of $202.62 and a 200-day simple moving average of $150.48. The company has a market capitalization of $1.46 billion, a PE ratio of 8.35 and a beta of 0.55. Nutex Health Inc. has a twelve month low of $83.99 and a twelve month high of $226.16. The company has a current ratio of 5.00, a quick ratio of 4.96 and a debt-to-equity ratio of 0.59.

Nutex Health (NASDAQ:NUTX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $9.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The firm had revenue of $210.75 million for the quarter, compared to the consensus estimate of $215.03 million. Equities research analysts anticipate that Nutex Health Inc. will post 27.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Nutex Health

In other news, Director Scott Saunders sold 203 shares of the firm's stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $214.25, for a total transaction of $43,492.75. Following the completion of the sale, the director directly owned 400 shares in the company, valued at $85,700. This trade represents a 33.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 44.68% of the stock is owned by corporate insiders.

Analyst Ratings Changes

NUTX has been the subject of several recent research reports. Wall Street Zen upgraded Nutex Health from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. Lake Street Capital restated a "buy" rating and set a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research note on Tuesday, August 11th. Weiss Ratings raised Nutex Health from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, October 6th. LADENBURG THALM/SH SH assumed coverage on Nutex Health in a research report on Monday. They issued a "buy" rating and a $336.00 target price for the company. Finally, B. Riley Financial reiterated a "buy" rating on shares of Nutex Health in a research note on Friday, September 4th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $323.67.

About Nutex Health

Nutex Health, Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.

Want to see what other hedge funds are holding NUTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nutex Health Inc. (NASDAQ:NUTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.